0001708138-20-000014.txt : 20200227 0001708138-20-000014.hdr.sgml : 20200227 20200227161241 ACCESSION NUMBER: 0001708138-20-000014 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200225 FILED AS OF DATE: 20200227 DATE AS OF CHANGE: 20200227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Van Plew Daniel P CENTRAL INDEX KEY: 0001411984 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 20662169 MAIL ADDRESS: STREET 1: REGENERON PHARMACEUTICALS, INC. STREET 2: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-02-25 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001411984 Van Plew Daniel P 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 EVP & General Mgr Industrial O Common Stock 2020-02-25 4 M 0 32735 30.63 A 60986 D Common Stock 2020-02-25 4 F 0 17093 447.3 D 43893 D Common Stock 2020-02-26 4 S 0 200 451.61 D 43693 D Common Stock 2020-02-26 4 S 0 300 452.53 D 43393 D Common Stock 2020-02-26 4 S 0 1000 453.57 D 42393 D Common Stock 2020-02-26 4 S 0 711 454.53 D 41682 D Common Stock 2020-02-26 4 S 0 1300 455.5 D 40382 D Common Stock 2020-02-26 4 S 0 1435 456.5 D 38947 D Common Stock 2020-02-26 4 S 0 3787 457.59 D 35160 D Common Stock 2020-02-26 4 S 0 5274 458.45 D 29886 D Common Stock 2020-02-26 4 S 0 1425 459.33 D 28461 D Common Stock 2020-02-26 4 S 0 210 460.3 D 28251 D Common Stock 1537 I By 401(k) Plan Non-Qualified Stock Option (right to buy) 30.63 2020-02-25 4 M 0 32735 0.0 D 2020-12-14 Common Stock 32735 0 D Represents volume-weighted average price of sales of 200 shares of Company stock on February 26, 2020 at prices ranging from $451.51 to $451.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 300 shares of Company stock on February 26, 2020 at prices ranging from $452.25 to $452.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 1,000 shares of Company stock on February 26, 2020 at prices ranging from $453.06 to $453.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 711 shares of Company stock on February 26, 2020 at prices ranging from $454.02 to $454.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 1,300 shares of Company stock on February 26, 2020 at prices ranging from $455.01 to $455.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 1,435 shares of Company stock on February 26, 2020 at prices ranging from $456.00 to $456.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 3,787 shares of Company stock on February 26, 2020 at prices ranging from $457.00 to $457.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 5,274 shares of Company stock on February 26, 2020 at prices ranging from $458.00 to $458.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 1,425 shares of Company stock on February 26, 2020 at prices ranging from $459.02 to $459.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. Represents volume-weighted average price of sales of 210 shares of Company stock on February 26, 2020 at prices ranging from $460.00 to $460.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price. The option became exercisable with respect to all shares underlying the option on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013. /s/**Daniel P. Van Plew 2020-02-27